Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
about
Adult-onset Still's disease: current challenges and future prospectsSafety of tocilizumab in the treatment of juvenile idiopathic arthritis.Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Treatment of adult-onset still's disease: up to date.Tocilizumab for treating juvenile idiopathic arthritis.Dendritic cell vaccines: A review of recent developments and their potential pediatric application.New frontiers in the treatment of systemic juvenile idiopathic arthritis.Spontaneous resolution of Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis in Still's disease treated by tocilizumab: a case report.Pharmacologic Treatment of Noninfectious Uveitis.Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting.Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
P2860
Q28079446-AD25B4C5-6141-419F-B82F-25B885BE6B8DQ30235357-0FA43C32-4C85-43F4-BA65-E11CB2B521B8Q37747792-97F00CE8-F717-4544-A6E3-20935B3BF602Q38679486-FD0B4D58-1F94-406D-B179-B65DE5518964Q38723988-7DAC78E4-BB99-49F5-8025-F7E4E428D208Q38849396-F568D851-E5DF-4A7E-AD85-CF9495723638Q39424746-C3752A6A-5237-447A-B931-7DF5622CF5B3Q40076637-3A118637-CC83-4003-913B-689A769F0100Q40450258-F82CAED6-F9C1-4F10-9586-5407328105B2Q40450982-EE8457BA-76E8-4A34-927E-9CDE9E95DAB8Q41994113-8D38F3DC-B20F-45F4-A80B-AB38D74F9DE8Q47111826-40A79072-78FE-4A2C-B156-D966E59BF0F5Q52330721-3072F64C-E83C-412E-8A56-2A74E69397E1
P2860
Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@en
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@nl
type
label
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@en
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@nl
prefLabel
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@en
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@nl
P2093
P2860
P1476
Tocilizumab in systemic juveni ...... w-up of 417 patients in Japan.
@en
P2093
Hideki Origasa
Kunihiko Tanaka
Minako Tomobe
Naokata Sumitomo
Seiji Minota
Shumpei Yokota
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-207818
P407
P577
2015-12-07T00:00:00Z